Critical review of GABA-ergic drugs in the treatment of schizophrenia

Journal of Clinical Psychopharmacology

Volumn 19, Issue 3, 1999, Pages 222-232

  Wassef, Adel A ^a   Dott, Sharon G ^b,c   Harris, Ann ^b   Brown, Alston ^b   O'Boyle, Michael ^b   Meyer III, Walter J ^b   Rose, Robert M ^d  

^a University of Texas Harris County Psychiatric Center   (United States)

^b UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^c Gulf Coast Mental Hlth Mental R   (United States)

^d John D and Catherine T MacArthur Foundation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE DERIVATIVE; GABAERGIC RECEPTOR AFFECTING AGENT; PROGABIDE; VALPROIC ACID;

4 AMINOBUTYRIC ACID RELEASE; ARTICLE; DOPAMINE RELEASE; DOPAMINERGIC TRANSMISSION; DRUG EFFECT; DRUG EFFICACY; GABAERGIC TRANSMISSION; HUMAN; MOLECULAR BIOLOGY; NERVE CELL NETWORK; PRIORITY JOURNAL; RECEPTOR BINDING; SCHIZOPHRENIA;

ANTI-ANXIETY AGENTS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CLINICAL TRIALS; DOPAMINE; GABA AGENTS; GAMMA-AMINOBUTYRIC ACID; HUMANS; NEURONS; RECEPTORS, GABA; SCHIZOPHRENIA; VALPROIC ACID;

EID: 0032956649     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-199906000-00004     Document Type: Article

References (49)

1. Hare TA, Wood JH, Ballenger JC, Post RM. Gamma-aminobutyric acid in human cerebrospinal fluid: normal values [letter]. Lancet 1979;8:534-5.
2. Lloyd K, Morselli P. Psychopharmacology of GABA-ergic drugs. In: Meltzer HY, ed. Psychopharmacology: the third generation of progress. New York: Raven Press, 1987:265-72.
3. Shelton R, Weinberger D. Brain morphology in schizophrenia. In: Meltzer HY, ed. Psychopharmacology: the third generation of progress. New York: Raven Press, 1987;773-81.
4. Wolkowitz O, Pickar D. Benzodiazepines in the treatment of schizophrenia: a review and appraisal. Am J Psychiatry 1991; 148:714-26.
5. Scatton B, Worms P, Lloyd KG, Bartholini G. Cortical modulation of striatal function. Brain Res 1982;232:331-43.
6. Losonczy M, Davidson M, Davis K. The dopamine hypothesis of schizophrenia. In: Meltzer HY, ed. Psychopharmacology: the third generation of progress. New York: Raven Press, 1987;715-26.
7. Bannon MJ, Roth RH. Pharmacology of mesocortical dopamine neurones. Pharmacol Rev 1983;35:53-68.
8. Reynolds G, Czudek C, Andrews H. Deficit and hemispheric asymmetry of GABA uptake sites in the hippocampus in schizophrenia. Biol Psychiatry 1990;27:1038-44.
9. Simpson M, Slater P, Deakin J, Royston M, Skan W. Reduced GABA uptake sites in the temporal lobe in schizophrenia. Neurosci Lett 1989;107:211-5.
10. Garbutt JC, Van Kammen DP. The interaction between GABA and dopamine: implications for schizophrenia. Schizophr Bull 1983; 9:336-53.
11. Jones MW, Kilpatrick IC, Phillipson OT. Dopamine function in the prefrontal cortex of the rat is sensitive to a reduction of tonic GABA mediated inhibition in the thalamic mediodorsal nucleus. Exp Brain Res 1988;69:623-34.
12. Reid M, Herrera Marschitz M, Hokfelt T, Terenius L, Ungerstedt U. Differential modulation of the striatal dopamine release by intranigral injection of gamma aminobutyric acid (GABA), dynorphin A and substance P. Eur J Pharmacol 1988;147:411-20.
13. Ishita S, Negishi K, Teranishi T, Shimada Y, Kato S. GABAergic inhibition on dopamine cells of the fish retina: a [3H]dopamine release study with isolated fractions. J Neurochem 1988;50:1-6.
14. MacDonald RL, McLean MJ. Mechanisms of anticonvulsant drug action. Electroencephalogr Clin Neurophysiol Suppl 1987;39: 200-8.
15. Onteniente B, Simon H, Taghzouti K, Geffard M, Le Moal M, Calas A. Dopamine GABA interactions in the nucleus accumbens and lateral septum of the rat. Brain Res 1987;421:391-6.
16. Penit-Soria J, Audinat E, Crepel F. Excitation of rat prefrontal cortical neurons by dopamine: an in vitro electrophysiological study. Brain Res 1987;425:263-74.
17. Waszczak B, Walters J. Effects of GABA mimetics on substantia nigra neurones. Adv Neurol 1979;123:727-40.
18. Monteleone P, Zontini G, Steardo L. Failure of the GABAergic drug, sodium valproate to reduce basal plasma prolactin secretion in chronic schizophrenia, Psychoneuroendocrinology 1985; 10:475-80.
19. Monteleone P, Maja M, Iovino M, Lyca S. Growth hormone response to sodium valproate in chronic schizophrenia. Biol Psychiatry 1986;21:588-94.
20. Orio F, Iovino M, Monteleone P, Argusta M, Steardo L, Lombardi G. Pharmacological activation of the GABA-ergic system does not affect GH and PRL release in acromegaly. Horm Metab Res 1988;20:701-4.
21. Freed W, Gillin C, Wyatt R. Anomalous behavioral response to imidazoleacetic acid, a GABA agonist, in animals treated chronically with haloperidol. Biol Psychiatry 1980;15:21-35.
22. Van Kammen DP, Gelernter J. Biochemical instability in schizophrenia. II: the serotonin and gamma-aminobutyric acid systems. In: Meltzer HY, ed. Psychopharmacology: the third generation of progress. New York: Raven Press, 1987:75-8.
23. Schwartz B. Early information processing schizophrenia. Psychiatr Med 1990;9:73-94.
24. Ko GN, Korpi ER, Freed WJ, Zaleman SJ, Bigelow LB. Effect of VPA on behavior and plasma amino acid concentrations in chronic schizophrenic patients. Biol Psychiatry 1985; 20:209-15.
25. Arnsten A. Dopamine mechanisms influencing prefrontal cognitive functioning in rats and monkeys. Scientific Abstracts of the 35th Annual Meeting of the American College of Neuropsychopharmacology (ACNP). San Juan, Puerto Rico, Dec 9-13, 1996:72.
26. Roberts K. Schneiderian first rank symptoms caused by benzodiazepine withdrawal. Br J Psychiatry 1986;148:593-4.
27. Korsgaard S, Casey D, Gerlach J, Hetmar O, Kaldan B, Mikklesen L. The effect of tetrahydroisoxazolopyridinol (THIP) in tardive dyskinesia. Arch Gen Psychiatry 1982;39:1017-21.
28. Morselli PL, Bossi L, Henry JF, Zarifian E, Bartholini G. On the therapeutic action of SL 76 002, a new GABA-mimetic agent: preliminary observations in neuropsychiatric disorders. Brain Res Bull 1980;5[suppl 2]:411-4.
29. Casey DE, Gerlach J, Gerhard M, Christensen TR. Gamma-acetylenic acid in tardive dyskinesia. Arch Gen Psychiatry 1980; 37:1376-9.
30. Thaker GK, Hare TA, Tamminga CA. GABA system: clinical research and treatment of tardive dyskinesia. Mod Probl Pharmacopsychiatry 1983;21:155-67.
31. Smith ME. A clinical study of chlorpromazine and chlordiazepoxide. Conn Med 1961;25:153-7.
32. Nishikawa T, Tsuda A, Tanaka M, Koga I, Uchida Y. Prophylactic effects of neuroleptics in symptom-free schizophrenics: roles of dopaminergic and noradrenergic blockers. Biol Psychiatry 1985; 20:1161-6.
33. Preisendorfer U, Zeise ML, Klee MR. Valproate enhances inhibitory postsynaptic potentials in hippocampal neurons in vitro. Brain Res 1987;435:213-9.
34. Rall TW, Schliefer LS. Drugs effective in the therapy of the epilepsies. In: Gilman AG, Rail TW, Nies AS, Taylor P, eds. The pharmacologic basis of therapeutics. 8th ed. New York: Pergamon Press, 1990:450-3.
35. Biggio G, Casu M, Corda MG, Vernaleone F, Gessa GL. Effect of muscimol, a GABA-mimetic agent, on dopamine metabolism in the mouse brain. Life Sci 1977;21:525-31.
36. Wassef A, Watson D, Morrison P, Bryant S, Flack J. Neurolepticvalproic acid combination in treatment of psychotic symptoms: a three-case report. J Clin Psychopharmacol 1989;9:45-8.
37. McElroy S, Keck P Jr, Pope H Jr. Sodium valproate: its use in primary psychiatric disorders. J Clin Psychopharmacol 1987;7:16-24.
38. Saito M, Inoue R. Diurnal fluctuation of serum level of sodium valproate and interaction with neuroleptics. FoUa Psychiatr Neurol Jpn 1980;34:297.
39. Ishizaki T, Chiba K, Saito M, Kobayashi K, Iizuka R. The effect of neuroleptics (haloperidol and chlorpromazine) on the pharmacokinetics of valproic acid in schizophrenic patients. J Clin Pharmacol 1984;4:254-61.
40. Lautin A, Angrist B, Stanley M, Gershon S, Heckl K, Karobath M. Sodium valproate in schizophrenia: some biochemical correlates. Br J Psychiatry 1980;137:240-4.
41. Nagao T, Ohshimo T, Mitsunobu K, Saito M, Otsuki S. Cerebrospinal fluid monamine metabolites and cyclic nucleotides in chronic schizophrenic patients with tardive dyskinesia or drug-induced tremor. Biol Psychiatry 1979;14:509-23.
42. Gündürewa V, Beckmann H, Zimmer R, Rüther E. Effect of VPA on schizophrenic syndromes. Arzneimittelforschung/Drug Res 1980;30:1212-3.
43. Linnoila M, Viukari M, Hietala O. Effect of sodium valproate on tardive dyskinesia. Br J Psychiatry 1976;129:114-9.
44. Altamura AC, Basile R, Mauri M, Cazzullo CL. Le valpromide dans le traitment d'etats psychotiques aigus: une etude clinique ouverte. Acta Psychiatr Belg 1986;86:297-304.
45. Morinigo A, Martin J, Gonzalez S, Mateo I. Treatment of resistant schizophrenia with valproate and neuroleptic drugs. Hillside J Clin Psychiatry 1989;11:199-207.
46. Spitzer RL, Endicott J, Robin E. Research diagnostic criteria: rationale and reliability. Arch Gen Psychiatry 1978;35:773-82.
47. Vandel S, Bertschy G, Jounet JM, Allers G. Valpromide increases the plasma concentrations of amitriptyline and its metabolite nortriptyline in depressive patients. Ther Drug Monit 1988;10:386-9.
48. Kane J, Honigfeld G, Singer J, Meltzer H, and the Clozaril Study Group. Clozapine for the treatment-resistant schizophrenia. Arch Gen Psychiatry 1988;45:769-89.
49. Small JG, Hirsch SR, Arvanitis LA, Miller BG, Link CGG. Quetiapine in patients with schizophrenia. A high-and low-dose double-blind comparison with placebo. Arch Gen Psychiatry 1997;54: 549-57.